Diluted HEPS from continuing operations of 51.9cps (1H25: -152.2cps). Normalised EPS up 8.4% y-y to 53.1cps.
Revenue growth from continuing operations +2.4% y-y to R12.4bn.
Total expenses declined by 19.1% y-y to R11 317m, with expenses-to-sales down to 91.1% (1H25: 115.3%).
The Piramal liability was paid during the period (1H25: -R2 920m) but remained with the subsidiary and all fair value adjustments to this liability and other overhead costs are included as part of the international segment.
An impairment of R29m was recognised relating to Life Health Solutions.
OPM from continuing operations improved to 10.0% (1H25: -14.1%).
Dividend of 23.0cps (1H25: 21.0cps).
Acute hospital PPD declined 0.9% y-y on a like-for-like basis. Occupancy on a like-fo-like basis down to 67.0% (1H25: 68.5%).
A dispute between Life Healthcare and Fresenius Medical Care (FMC) in relation to the acquisition of FMC’s South African and Namibian renal dialysis businesses is ongoing.
Complementary services occupancies up to 72.7% (1H25: 71.6%). Diagnostics continued to perform well, with MRI, CT, PET-CT and SPECT volumes growing by 4.2% y-y.
